NEW YORK, Jan. 15-Celera Diagnostics has secured a license to Variagenics' patents on a set of polymorphisms in a gene related to thromboembolic disease risk, Variagenics said yesterday.
The license, which is global and non-exclusive, allows Celera Diagnostics to commercialize products that detect variations in the gene for methylenetetrahydrofolate reductase, which has been associated with cardiovascular disease, myocardial infarction and stroke.
Celera plans to develop analyte specific reagents and, ultimately, in vitro diagnostics.
The companies did not reveal financial details of the agreement.
The gene may also be important in central nervous system disease, osteoporosis, folic acid metabolic diseases, and cancer, and Variagenics will retain the right to develop pharmacogenomic tests for these illnesses.
Variagenics acquired patent rights for MTHFR from McGill University in 1999, and researchers at the university and the company have continued to work together to find pharmacogenomic markers associated with the gene.